European Society of Cardiology Congress

According to late breaking data, younger women exhibit a decreased risk for heart attack mortality due to estrogen’s protective effect

What ESC has learned about the benefits and difficulties of online-only forums.

Evolocumab and alirocumab produced LDL-C reduction in patients regardless of underlying mutations, investigators reported.

This underscores a need to reinvent cities and address environmental risk factors that are associated with increased risk for cardiovascular diseases.

Myocardial infarction patients were provided ECG readings as reliable as those provided by standard devices.

Studies have shown that heat-related cardiovascular events have increased over recent years.

New cohort data shows that at least 40% of COVID-19 positive patients had CV risk factors, such as diabetes and hypertension.

Dapagliflozin and empagliflozin are shown to minimize CV events in patients with heart failure and a reduced ejection fraction.

A look at how a major international cardiovascular meeting changed its structure in 4 months.

A look at how different organisms are influenced differently by harmful foods or common therapies linked to cardiovascular risks.

Investigators did note that belief in statin use was weaker in patients with confirmed statin associated muscle symptoms when compared with non-SAMS patients.

New findings suggest the "obesity paradox" may be explained by rates of exercise among women.

Accurately assessing lifetime risk in patients with developing atherosclerosis may help reduce CV disease risk earlier in life.

The CLEAR Harmony open-label extension study reports on the long-term effects of BA treatment for hypercholesterolemia.

The new findings break ground on placebo-controlled assessment of the PCSK9 inhibitor for the pediatric population.

Up to 91% patients who received maximum dosage of the drug achieved a triglyceride level of <150 mg/dL, according to new data presented at ESC 2020.

A look at how asymptomatic AFib is being combatted by consumer devices and embraced, large-scale population research.

New cohort analyses show very few patients with atrial fibrillation exercise regularly or rigorously—which could be a detriment to their mortality risk.

Daniel Gaudet, MD, PhD, discusses what's next in clinical pursuits of the greatly underdiagnosed hereditary cardiovascular disease.

Investigators simulated baseline CV risk and predicted potential risk reduction among a cohort of evolocumab users across Europe.

A podcast interview with the president of American Society of Preventive Cardiology, on the eve of the ESC 2020 Congress.

PCSK9 inhibitor therapy within 24 hours after PCI was shown to bring LDL-C levels down closer to guideline-recommended goals.

At The European Society of Cardiology Congress 2016 (ESC), Ibrahim Danad, MD, VU University Medical Center, Amsterdam, Netherlands, explained the results from his team's PACIFIC trial, which assessed two non-invasive coronary artery imaging tools: positon emission tomography (PET) and single photon emission computed tomography (SPECT).

At the European Society of Cardiology Congress 2016 (ESC) in Rome, Italy, Anselm Gitt, MD discussed the DYSIS program, which was designed to get an idea to see how patients were treated for secondary prevention, focusing on dyslipidemia patients.

Renato Delascio Lopes, MD, Duke University Medical Center, discussed at the European Society of Cardiology Congress 2016 (ESC), the progress of anticoagulant therapies for patients.

Christopher Granger, MD, Duke University Medical Center also spoke at the European Society of Cardiology COngress 2016 about the issues surrounding patients' tolerability of anticoagulants and other drugs.

Statins should not be physicians' first option in treating all patients at high risk of cardiovascular disease, according to new European treatment guidelines.

An international team looked at oral anticoagulants and decided dabigatran is the best for stroke prevention in non-valvular atrial fibrillation.

Lung cancer patients who develop sinus tachycardia due to some treatments for their cancer can successfully reduce their heart rates with ivabradine, researchers in Romania report.

Pope Francis plans to appear at the ESC Congress 2016 to endorse the group's healthy lifestyle campaign.